Notice of Proposed Sale · 144
Rockwell Medical, Inc.
RMTINASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ROCKWELL MEDICAL, INC.
- Issuer CIK
- 0001041024
- SEC file number
- 000-23661
- Phone
- 8004493353
- Person for whose account securities are to be sold
- Strobeck Mark
- Relationships to issuer
- Officer
- Street
- 30142 WIXOM ROAD
- City
- WIXOM
- State / country code
- MI
- Postal code
- 48393
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,000 | 8,400.00 | 4,030,465 | 10/01/2026 | Nasdaq | Raymond James & Associates, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- Raymond James & Associates, Inc.
- Street
- 880 Carillon Parkway
- City
- St. Petersburg
- State / country code
- FL
- Postal code
- 33716
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 03/14/2025 | RSU Vesting | Issuer | 4,763 | N | 03/14/2025 | RSU Vesting |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 10/01/2026
- Signed
- Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Mark Strobeck
- Plan adoption dates
- 05/19/2026
Company context
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & ProductionTM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions TM. For more information, visit www.rockwellmed.com.